A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range

Journal of Urology

Volumn 185, Issue 5, 2011, Pages 1650-1655

  Catalona, William J ^a   Partin, Alan W ^b   Sanda, Martin G ^c   Wei, John T ^d   Klee, George G ^e   Bangma, Chris H ^f   Slawin, Kevin M ^g   Marks, Leonard S ^h   Loeb, Stacy ^b   Broyles, Dennis L ⁱ   Shin, Sanghyuk S ⁱ   Cruz, Amabelle B ⁱ   Chan, Daniel W ^b   Sokoll, Lori J ^b   Roberts, William L ^j   Van Schaik, Ron H N ^f   Mizrahi, Isaac A ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MAYO CLINIC   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Texas Prostate Center   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BECKMAN COULTER INC   (United States)

^j ARUP LABORATORIES   (United States)

more..

Author keywords

diagnosis; mass screening; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

[-2] PRO PROSTATE SPECIFIC ANTIGEN; FREE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; AREA UNDER CURVE; BIOPSY; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79953777963     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.12.032     Document Type: Article

References (30)

1. J.S. Krumholtz, G.F. Carvalhal, and C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469
2. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 350 2004 2239
3. W.J. Catalona, J.P. Richie, and F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283
4. H. Lilja, A. Christensson, and U. Dahlen Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin Clin Chem 37 1991 1618
5. W.J. Catalona, A.W. Partin, and K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542
6. S.D. Mikolajczyk, W.J. Catalona, and C.L. Evans Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 2004 1017
7. S.D. Mikolajczyk, L.S. Grauer, and L.S. Millar A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum Urology 50 1997 710
8. T.Y. Chan, S.D. Mikolajczyk, and K. Lecksell Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen Urology 62 2003 177
9. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 2003 2181
10. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen J Urol 171 2004 2239
11. L.J. Sokoll, D.W. Chan, and S.D. Mikolajczyk Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis Urology 61 2003 274
12. L.J. Sokoll, Y. Wang, and Z. Feng [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study J Urol 180 2008 539
13. L.J. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193
14. F.H. Schrder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
15. G.L. Andriole, R.L. Grubb 3rd, and S.S. Buys Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310
16. H.G. Welch, and P.C. Albertsen Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 2009 1325
17. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725
18. D.V. Makarov, S. Isharwal, and L.J. Sokoll Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer Clin Cancer Res 15 2009 7316
19. F.H. Jansen, R.H. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921
20. A. Semjonow, T. Kopke, and E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 43 2010 926
21. G. Qin, Y.S. Hsu, and X.H. Zhou New confidence intervals for the difference between two sensitivities at a fixed level of specificity Stat Med 25 2006 3487
22. D.W. Hosmer, and S. Lemeshow Applied Logistic Regression 1989 John Wiley & Sons New York
23. B. Efron The Jackknife, the Bootstrap, and Other Resampling Plans 1982 Society for Industrial and Applied Mathematics Philadelphia
24. B. Efron Better bootstrap confidence intervals J Am Stat Assoc 82 1987 171
25. M.S. Pepe The Statistical Evaluation of Medical Tests for Classification and Prediction 2003 Oxford University Press New York
26. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
27. S.H. de Vries, R. Raaijmakers, and B.G. Blijenberg Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer Urology 65 2005 926
28. Y. Naya, H.A. Fritsche, and V.A. Bhadkamkar Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer Urol Oncol 23 2005 16
29. Isharwal S, Makarov DV, Sokoll LJ, et al. Prostate Health Index and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program. Unpublished data.
30. S. Loeb, D.W. Chan, and L. Sokoll Prostate specific antigen assay standardization bias could affect clinical decision making J Urol 180 2008 1959